Literature DB >> 14984318

Serum levels of IGF-I, HGF, TGFbeta1, bFGF and VEGF in thyroid gland tumors.

D Veselý1, J Astl, P Lastůvka, P Matucha, I Sterzl, J Betka.   

Abstract

IGF-I, HGF, TGFbeta1, bFGF and VEGF are involved in the pathogenesis of thyroid gland tumors and their growth. We decided to find whether changes in the production of these cytokines by thyroid tumor cells are reflected by changes of their peripheral blood. Using ELISA kits, we measured the concentrations of growth factors in the peripheral blood serum in 28 patients with thyroid gland tumors (14 adenomas, 14 papillary carcinomas) and compared these concentrations with those in healthy people. We found significantly lower serum levels of IGF-I in patients with thyroid adenoma compared to the healthy population. Serum levels of HGF and bFGF were significantly higher in patients with thyroid adenoma and papillary carcinoma compared with those in healthy subjects. Serum concentrations of TGFbeta1 and VEGF were not significantly different in any groups of investigated subjects. Changes in the production of these cytokines by thyroid gland tumor cells are reflected in their peripheral blood levels, but these levels also depend on a number of other physiological and pathological processes in the organism. However, significant differences of HGF and bFGF serum levels can be explained by their very high production by thyroid tumor cells and by their strong effect on the follicular and endothelial cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14984318

Source DB:  PubMed          Journal:  Physiol Res        ISSN: 0862-8408            Impact factor:   1.881


  12 in total

1.  Role of growth factors on human parathyroid adenoma cell proliferation.

Authors:  Giuseppe Cavallaro; Alessandra Cucina; Pierpaolo Coluccia; Luigi Petramala; Dario Cotesta; Andrea Polistena; Laura Zinnamosca; Claudio Letizia; Lodovico Rosato; Antonino Cavallaro; Giorgio De Toma
Journal:  World J Surg       Date:  2010-01       Impact factor: 3.352

Review 2.  Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.

Authors:  Devron R Shah; Rashmi R Shah; Joel Morganroth
Journal:  Drug Saf       Date:  2013-06       Impact factor: 5.606

3.  Decellularized periodontal ligament cell sheets with recellularization potential.

Authors:  A Farag; C Vaquette; C Theodoropoulos; S M Hamlet; D W Hutmacher; S Ivanovski
Journal:  J Dent Res       Date:  2014-09-30       Impact factor: 6.116

4.  Interleukins as markers of inflammation in malignant and benign thyroid disease.

Authors:  Xeni Provatopoulou; Despoina Georgiadou; Theodoros N Sergentanis; Eleni Kalogera; John Spyridakis; Antonia Gounaris; George N Zografos
Journal:  Inflamm Res       Date:  2014-05-03       Impact factor: 4.575

5.  Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases.

Authors:  Faina Linkov; Robert L Ferris; Zoya Yurkovetsky; Adele Marrangoni; Lyudmila Velikokhatnaya; William Gooding; Brian Nolan; Matthew Winans; Eric R Siegel; Anna Lokshin; Brendan C Stack
Journal:  Proteomics Clin Appl       Date:  2008-10-10       Impact factor: 3.494

6.  Serum hepatocyte growth factor is increased in Hashimoto's thyroiditis whether or not it is associated with nodular goiter as compared with healthy non-goitrous individuals.

Authors:  R M Ruggeri; S Sciacchitano; A Vitale; P Cardelli; M Galletti; E Vitarelli; G Barresi; S Benvenga; F Trimarchi; M Trovato
Journal:  J Endocrinol Invest       Date:  2009-03-25       Impact factor: 4.256

Review 7.  IGF Bioregulation System in Benign and Malignant Thyroid Nodular Disease: A Systematic Review.

Authors:  Apostolos Karagiannis; Eva Kassi; Antonios Chatzigeorgiou; Michael Koutsilieris
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

8.  EGF and TGF-β1 Effects on Thyroid Function.

Authors:  Gabriella Mincione; Maria Carmela Di Marcantonio; Chiara Tarantelli; Sonia D'Inzeo; Arianna Nicolussi; Francesco Nardi; Caterina Francesca Donini; Anna Coppa
Journal:  J Thyroid Res       Date:  2011-06-13

9.  Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients.

Authors:  Yutaka Fujiwara; Naomi Kiyota; Naoko Chayahara; Akiyuki Suzuki; Yoshiko Umeyama; Toru Mukohara; Hironobu Minami
Journal:  Invest New Drugs       Date:  2011-02-08       Impact factor: 3.850

Review 10.  Molecular and pathological signatures of epithelial-mesenchymal transitions at the cancer invasion front.

Authors:  Olivier De Wever; Patrick Pauwels; Bram De Craene; Michèle Sabbah; Shahin Emami; Gérard Redeuilh; Christian Gespach; Marc Bracke; Geert Berx
Journal:  Histochem Cell Biol       Date:  2008-07-22       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.